PERKINS ADELENE Q (Chief Executive Officer) sold 25.9% of their position (410.20K shares) of INFINITY PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $28.7K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/12/2023ACC: 0000899243-23-018762
DirectorOfficer· Chief Executive Officer
Since Oct 2018
-410.20K
Net shares
Net seller
$28.7K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
768.13K acquired · 1.18M disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+768.13K
Price / share
—
Trade value
—
% of position
94.0%
9/9/2023
817.35K→1.59M
Common Stock
Direct
Shares
−410.20K
Price / share
$0.07
Trade value
$28.71K
% of position
25.9%
9/12/2023
1.59M→1.18M
Total
Net shares
+357.94K
Net value
-$28.71K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/9/2023 | M · Option Exercise | +768.13K | — | — | 94.0% | 817.35K | 1.59M |
| Common Stock Direct | 9/12/2023 | S · Sale | −410.20K | $0.07 | $28.71K | 25.9% | 1.59M | 1.18M |
| Total | +357.94K | -$28.71K | ||||||
Derivative Transactions1
Restricted Stock Unit
Direct
Converts to
Common Stock
768.13K shares
Shares
−768.13K
Strike price
Held after
0.00
Exercisable
—
9/9/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Unit Direct | Common Stock768.13K shares | 9/9/2023 | M · Option Exercise | −768.13K | — | 0.00 |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned16.45K
Total
16.45K indirect16.45K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 16.45K | Indirect |
| Total | 16.45K | 16.45K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported